Top Tweets for #pxt3003
@Pharnext announces database lock for #PXT3003 pivotal Phase 3 clinical study (PREMIER trial) in #CharcotMarieTooth disease type 1A, last step before topline results publication.
Read our press release: https://t.co/PMQNLUZ68z
@Pharnext annonce le gel de la base de données de l'étude clinique pivot de Phase 3 (essai PREMIER) de #PXT3003 dans la maladie de #CharcotMarieTooth de type 1A, dernière étape avant la publication des premiers résultats.
Lire notre communiqué : https://t.co/klAnuT5QXP
@Pharnext announces the successful manufacturing of the 3 registration batches of #PXT3003 oral solution sachets, and initiated the new drug application registration stability at @UnitherPharma.
Read ou press release: https://t.co/YeRknQizrJ
@Pharnext a réalisé avec succès la production des 3 lots d'enregistrement de #PXT3003 à l'usine américaine d'@UnitherPharma, et initié l’étude de stabilité d’enregistrement pour le dossier de demande de nouveau médicament.
Lire notre communiqué : https://t.co/R7ez9X3jZE
@Pharnext updates on the development program in China for its drug candiidate #PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A).
Read our press release: https://t.co/T5dVLZHuqf
#CharcotMarieTooth
L'équipe de @Pharnext participe aux 27e Journées de la Société Francophone du Nerf Périphérique (#SFNP) aujourd'hui et demain.
Si vous êtes sur place, venez nous rencontrer sur notre stand pour parler de notre #PXT3003 en Phase 3 dans la maladie de #charcotmarietooth.
@Pharnext supports and participates in the 27th Francophone Peripheral Nerve Society event (#SFNP) on March 10-11, 2023.
We'll host a booth to talk about our #PXT3003 in pivotal Phase 3 clinical development in #charcotmarietooth.
Read our press release: https://t.co/KRGmbzcISg
Ahead of #RareDiseaseDay, we’re highlighting #CharcotMarieTooth disease, the target of our drug candidate #PXT3003
CMT is one of the most common rare diseases but it lacks approved curative medicines. Methods consist of supportive care, occupational therapy or surgery.
#RDD23
@Pharnext unveils the latest progress of the PREMIER trial, pivotal Phase 3 clinical trial of #PXT3003 in #CharcotMarieTooth disease type 1A. #CMT
Read our press release: https://t.co/62mtRZbR7W
Breaking News: @Pharnext Announces On-Schedule Completion of Patient Enrollment in its Pivotal Phase III Trial of #PXT3003, PREMIER Trial, for Treatment of #CharcotMarieToothDisease 1A (#CMT1A)! @AllisonTMoore https://t.co/9ITCC32ISx #cmtwegotthis #Pharnext
#Pharnext annonce l’achèvement du recrutement de patients atteints de la maladie de #CharcotMarieTooth de type 1A dans l'essai pivot de Phase III de #PXT3003, l'essai PREMIER, selon le calendrier prévu.
Retrouvez notre communiqué de presse : https://t.co/6YDgPaAc0M
Pharnext's PXT3003, a potential treatment for Charcot–Marie–Tooth type 1A (CMT1A), continues to show sustained safety and efficacy in a Phase 3 open-label extension study. Data collected in April show... #CMT1A #OverallNeuropathyLimitationsScale #Pharnext https://t.co/pjAXI1w4mV
Update 👏 @Pharnext #PXT3003 Clinical Trial; “New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients w/ #CharcotMarieTooth Disease Type 1A after 5 yrs of total trial time!”@teaminspire 🧬 #cmt1a https://t.co/IKdfBssd8E
Do you have CMT1A? Our partner @Pharnext is actively recruiting CMT1A patience for #PXT3003 phase III trial!! Learn more here https://t.co/jEuvMsAqwH #charcotmarietoothdisease #cmtwegotthis #pharnext #clinicaltrials #charcotmarietooth
For #RareDiseaseDay2022, @Pharnext supports a global ‘Living with CMT’ Art Competition run by @ECMTF, @CMTNeuropathy and @CMTASTAR.
Learn more: https://t.co/3FXcmO6Au4
Let’s raise awareness of #CMT1A, the target of our lead drug candidate #PXT3003: https://t.co/D4CDGYRbze
“…In our study people not just remained stable, they improved,” said Florian Thomas, Founding Chair & Professor @HackensackUMC on the performance of #PXT3003.
Watch highlights of the event: https://t.co/MrTzYWQ01g
#Rdday #webinar #Pharnext #CharcotMarieTooth
"… dans notre étude, les patients n’ont pas montré une simple stabilisation mais une amélioration" a rappelé le Pr Florian Thomas @HackensackUMC à propos du #PXT3003.
Extraits de notre Journée R&D 2021 : https://t.co/NYizoAOWOe
#Pharnext #CharcotMarieTooth
David H. Solomon, DG de #Pharnext, présente dans une nouvelle vidéo les avancées de notre essai PREMIER (Phase 3), de notre étude d'extension et de notre récent financement. $ALPHA
Retrouvez-le s’exprimer depuis notre site internet : https://t.co/vhoxjD84y3
#interview #CMT
Last Seen Hashtags on Sotwe
反差婊
Seen from Thailand
Manipur
Unexpected ()*********************
Seen from United States
武侯
Seen from United States
ngintip
Seen from Indonesia
teenageers
futa #ai creampie
Seen from Puerto Rico
snaphack
Seen from United States
Chem2Dmat2025
Seen from United States
mgai()(()**(****))*video
Seen from South Africa
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
118.8M followers
Cristiano Ronaldo
@cristiano
114.5M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.8M followers
YouTube
@youtube
68.7M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.2M followers
CNN
@cnn
61.7M followers
X
@x
60.7M followers